[go: up one dir, main page]

MX2022005491A - Tratamientos contra esclerosis sistémica. - Google Patents

Tratamientos contra esclerosis sistémica.

Info

Publication number
MX2022005491A
MX2022005491A MX2022005491A MX2022005491A MX2022005491A MX 2022005491 A MX2022005491 A MX 2022005491A MX 2022005491 A MX2022005491 A MX 2022005491A MX 2022005491 A MX2022005491 A MX 2022005491A MX 2022005491 A MX2022005491 A MX 2022005491A
Authority
MX
Mexico
Prior art keywords
î2rî
systemic sclerosis
ssc
antagonists
ligand
Prior art date
Application number
MX2022005491A
Other languages
English (en)
Inventor
Ravindra Kumar
Gang Li
Oliveira Pena Janethe De
Joseph Grattin Reynolds
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MX2022005491A publication Critical patent/MX2022005491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En determinados aspectos, la presente descripción se refiere a métodos para el tratamiento contra la esclerosis sistémica (SSc) utilizando antagonistas de TßRII que comprenden un dominio heterólogo y una porción truncada de unión al ligando del dominio extracelular del polipéptido TßRII útil para antagonizar selectivamente un ligando de TßRII. La descripción además proporciona métodos para el tratamiento contra una o más complicaciones de SSc, que incluyen enfermedad pulmonar intersticial (ILD), con antagonistas de TßRII de la presente descripción.
MX2022005491A 2019-11-05 2020-11-04 Tratamientos contra esclerosis sistémica. MX2022005491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930941P 2019-11-05 2019-11-05
PCT/US2020/058967 WO2021092079A1 (en) 2019-11-05 2020-11-04 Treatments for systemic sclerosis

Publications (1)

Publication Number Publication Date
MX2022005491A true MX2022005491A (es) 2022-07-27

Family

ID=75849172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005491A MX2022005491A (es) 2019-11-05 2020-11-04 Tratamientos contra esclerosis sistémica.

Country Status (4)

Country Link
US (1) US20240226235A1 (es)
EP (1) EP4054617A4 (es)
MX (1) MX2022005491A (es)
WO (1) WO2021092079A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230137092A1 (en) * 2020-02-06 2023-05-04 Emerald Health Pharmaceuticals Inc. Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis
US20240277806A1 (en) * 2021-06-11 2024-08-22 Acceleron Pharma Inc. Actrii proteins and uses thereof
GB202302820D0 (en) * 2023-02-27 2023-04-12 Keybioscience Ag ProC3 and TGFBI in cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808934A (pt) * 1997-04-18 2000-08-01 Biogen Inc Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
EP1087998A1 (en) * 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
US20040038856A1 (en) * 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
AU2003287332A1 (en) * 2002-11-01 2004-06-07 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
ES2409756T3 (es) * 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
WO2015027082A1 (en) * 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
CN108348578B (zh) * 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
US20190218262A1 (en) * 2016-09-15 2019-07-18 Acceleron Pharma Inc. Twisted gastrulation polypeptides and uses thereof
AU2018205233A1 (en) * 2017-01-07 2019-07-11 Merck Patent Gmbh Dosing regimens and dosage forms for targeted TGFβ inhibition
PL3628049T3 (pl) * 2017-05-04 2023-09-25 Acceleron Pharma Inc. Białka fuzyjne receptora TGF-beta typu II i ich zastosowania
JP7654402B2 (ja) * 2018-02-09 2025-04-01 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
WO2019213446A1 (en) * 2018-05-03 2019-11-07 Acceleron Pharma Inc. NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF

Also Published As

Publication number Publication date
EP4054617A4 (en) 2023-12-27
EP4054617A1 (en) 2022-09-14
US20240226235A1 (en) 2024-07-11
WO2021092079A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
MX2022005491A (es) Tratamientos contra esclerosis sistémica.
ZA202300423B (en) Fusion constructs and methods of using thereof
PH12022550932A1 (en) Glp-1r modulating compounds
EP4431109A3 (en) Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
NZ770183A (en) Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
ZA201804513B (en) Method of treating c3 glomerulopathy
MX2024015540A (es) Polipeptidos quimericos para usarse en el tratamiento de la hemofilia a
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
NZ743935A (en) Transaction and id cards having selected texture and coloring
WO2019246262A3 (en) Methods of treating or inhibiting onset of huntington's disease
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
IL209854A (en) Polypeptide, an amino acid sequence encoded for this polypeptide, and the use of this polypeptide for the preparation of a cancer suppressant
NZ611108A (en) Methods of treating fgf21-associated disorders
NZ606195A (en) Methods and compositions for liver cancer therapy
WO2005113590A3 (en) Bmp10 propeptides and related methods
PH12020552088A1 (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
SA519401062B1 (ar) التحكم في التحويل في الزمن الفعلي لعمليات المعالجة بالتحفيز باستخدام التعرج وتحليل الخفض
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
NZ600079A (en) A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
PH12022550239A1 (en) Anti-ms4a4a antibodies and methods of use thereof
MX2022010021A (es) Anticuerpos de pilra y sus metodos de uso.